C. Van Sant

651 total citations
5 papers, 546 citations indexed

About

C. Van Sant is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, C. Van Sant has authored 5 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Molecular Biology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Epidemiology. Recurrent topics in C. Van Sant's work include Virus-based gene therapy research (2 papers), Herpesvirus Infections and Treatments (2 papers) and Cancer therapeutics and mechanisms (1 paper). C. Van Sant is often cited by papers focused on Virus-based gene therapy research (2 papers), Herpesvirus Infections and Treatments (2 papers) and Cancer therapeutics and mechanisms (1 paper). C. Van Sant collaborates with scholars based in United States, Czechia and Netherlands. C. Van Sant's co-authors include Bernard Roizman, Yasushi Kawaguchi, Peter W. Krug, Yurui Chang, Amy E. Sears, Isa K. Mushahwar, James W. Scheffel, Sukumar P. Desai, Robert J. Carrick and Richard J. Johnson and has published in prestigious journals such as Journal of Virology, Annals of Oncology and Journal of Medical Virology.

In The Last Decade

C. Van Sant

5 papers receiving 538 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Van Sant United States	4	367	214	150	129	112	5	546
Joana Loureiro Portugal	11	233 0.6×	276 1.3×	147 1.0×	27 0.2×	82 0.7×	13	593
Laura Arribillaga Spain	14	188 0.5×	163 0.8×	516 3.4×	64 0.5×	175 1.6×	22	819
Astrid Zahn Canada	12	157 0.4×	188 0.9×	184 1.2×	44 0.3×	64 0.6×	19	509
Sanami Takada Japan	12	431 1.2×	262 1.2×	80 0.5×	85 0.7×	101 0.9×	26	640
Donna Hempel United States	10	111 0.3×	153 0.7×	163 1.1×	156 1.2×	126 1.1×	14	471
Kara Carter United States	10	237 0.6×	222 1.0×	189 1.3×	64 0.5×	267 2.4×	17	670
Darin Takemoto United States	5	287 0.8×	267 1.2×	80 0.5×	36 0.3×	120 1.1×	6	541
David J. Kittlesen United States	7	250 0.7×	372 1.7×	650 4.3×	53 0.4×	197 1.8×	8	993
Yuji Sobao Japan	11	222 0.6×	121 0.6×	420 2.8×	19 0.1×	121 1.1×	14	627
Stany Depraetere Belgium	9	87 0.2×	77 0.4×	178 1.2×	37 0.3×	36 0.3×	13	404

Countries citing papers authored by C. Van Sant

Since Specialization

Citations

This map shows the geographic impact of C. Van Sant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Van Sant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Van Sant more than expected).

Fields of papers citing papers by C. Van Sant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Van Sant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Van Sant. The network helps show where C. Van Sant may publish in the future.

Co-authorship network of co-authors of C. Van Sant

This figure shows the co-authorship network connecting the top 25 collaborators of C. Van Sant. A scholar is included among the top collaborators of C. Van Sant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Van Sant. C. Van Sant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Benson, Al B., John Bridgewater, Ferry A.L.M. Eskens, et al.. (2014). Baton-Crc: a Phase 2 Randomized Trial Comparing Tivozanib (Tivo) + Mfolfox6 with Bevacizumab (Bev) + Mfolfox6 in Stage Iv Metastatic Colorectal Cancer (Mcrc). Annals of Oncology. 25. iv182–iv182. 3 indexed citations

2.

Kelly, Ronan J., Anish Thomas, Arun Rajan, et al.. (2013). A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Annals of Oncology. 24(10). 2601–2606. 128 indexed citations

3.

Kawaguchi, Yasushi, C. Van Sant, & Bernard Roizman. (1997). Herpes simplex virus 1 alpha regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3. Journal of Virology. 71(10). 7328–7336. 224 indexed citations

4.

Chang, Yurui, C. Van Sant, Peter W. Krug, Amy E. Sears, & Bernard Roizman. (1997). The null mutant of the U(L)31 gene of herpes simplex virus 1: construction and phenotype in infected cells. Journal of Virology. 71(11). 8307–8315. 101 indexed citations

5.

Lesniewski, Richard R., Richard J. Johnson, James W. Scheffel, et al.. (1995). Antibody to hepatitis C virus second envelope (HCV‐E2) glycoprotein: A new marker of HCV infection closely associated with viremia. Journal of Medical Virology. 45(4). 415–422. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact